Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Obesity and pharmacologic therapy.

Marie Thearle1, Louis J Aronne

  • 1Department of Preventive Medicine, Columbia University College of Physicians and Surgeons, Russ Berrie Medical Science Pavilion, 1150 St. Nicholas Avenue, Room 238, New York, NY 10032, USA.

Endocrinology and Metabolism Clinics of North America
|January 9, 2004
PubMed
Summary

Obesity pharmacologic treatments significantly improve weight loss compared to diet alone. This medical intervention also enhances blood pressure, insulin sensitivity, and dyslipidemia in patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial.

Lancet (London, England)·2026
Same author

Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial.

Nature medicine·2026
Same author

A Rare Case of Cutaneous Lymphomatoid Granulomatosis: A Case Report and Literature Review.

Cureus·2026
Same author

Prevalence and predictors of patient-directed discharge in patients with opioid use disorder.

General hospital psychiatry·2026
Same author

Reversion to normoglycemia with tirzepatide vs semaglutide in participants with obesity and prediabetes: a post hoc analysis of SURMOUNT-5.

Journal of endocrinological investigation·2026
Same author

Relationship of early rapid weight loss to efficacy and safety of tirzepatide and semaglutide for obesity: SURMOUNT-5 post hoc analysis.

The American journal of medicine·2026

Area of Science:

  • Endocrinology
  • Metabolic Disorders
  • Pharmacology

Background:

  • Obesity is a prevalent, complex, multifactorial chronic disease.
  • Lifestyle modifications show limited success in managing obesity.
  • Current treatments include sibutramine and orlistat, offering greater weight loss than diet alone.

Purpose of the Study:

  • To review the efficacy of current pharmacologic obesity treatments.
  • To highlight the metabolic benefits associated with weight loss from medical therapy.
  • To provide an overview of emerging obesity therapies in clinical trials.

Main Methods:

  • Review of current literature on pharmacologic obesity treatments.
  • Analysis of weight loss data comparing pharmacologic interventions with lifestyle modification.

Related Experiment Videos

  • Examination of associated metabolic improvements.

    • Main Results:

    • Pharmacologic treatments like sibutramine and orlistat yield greater weight loss than diet alone.
    • A higher proportion of patients on medical treatment achieve >5-10% body weight loss.
    • Achieved weight loss correlates with improvements in blood pressure, insulin sensitivity, and dyslipidemia.

    Conclusions:

    • Pharmacologic therapy is an effective strategy for significant weight loss in obesity.
    • Medical treatment of obesity offers substantial cardiometabolic health benefits.
    • Numerous novel obesity therapies targeting diverse pathways are under development.